{"name":"Xalud Therapeutics, Inc.","slug":"xalud-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLVlJc3JXdTZCR3pKMHhLclJMV0NhYksyQzJjZm5vOENGSUFQRzFIdHBvdzFvYXB3a3pSWGQ3RWtHZEpHMEJJcHZJXy1HdnNsejQ3TzV0bmZoenBMeFBCbjZwWERaekl3ZVJ4amcxNDlkZzJlM2V4VXgwLVdKSnhXYzFMSUVtcUkzNHlTei1IM254eF9TeHBQZzJR?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com","headline":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxOSWpzRXhOUlZTRWN6VFRNZzNkSE5jaTF6cjE4UWpDR09lQ2NvWVhGMTRlVmNiaWdmLXJtbmtma2cxWk9SZDl4aFJUUzY1ZVVCcDJoUHZiQkhvck8tTE9Tcm1XSVhuTXNIVFBCaENzT1dYWm1RS1lLN3Vmb01zcGhGQjBvcDEwek05cWFxcHJaWHZxNDlfMnVHRDRPWTROckJZUzJrVUtJMHhVd0tMMGkyRU9UNWNGa1lKTGpheTlSd1lER3FheTBqZ1ZYZ2c1RVdFSHliOTBnckxoVVd2ci1HRE1RZW1KRGxseU9qX2VIbHA5bUZHQTEtbnRCdWVoY2JrZE83Mk9SYk1FaGhPVDJiQnhhTEk3VkpDZTNvRFFZb2FNendIMlR0QkpRZHJFUFdn?oc=5","date":"2025-11-18","type":"pipeline","source":"PR Newswire","summary":"Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight - PR Newswire","headline":"Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOZlJiMnRjTzZuTGFPQUdmU2g1UEpFdnE0YVJuS1ozOHpFYWFWc19rNHFRNkF6Z1dYX2dPSzJrVDNsOE5RSXh3NFZzWFlMdHotR2xURzFPaW81ZUZacGdsNFNXS1piWElJaHdPcTZLWWpNeUc1SzZjNzFQa2lkQlRWOGk4aDhOYml5aTJCTUhha0J2R3ZCdmRoOWZhMTVNNXVwMzVzak1ibEF0VkFTOTVRZGIzc0diQURWNEpIMzI0SlRuUWhCSzM2MXRjSkFheklGczU4UmNaZVN3WmZFZnRLTG5ZTU5BU2ZkRjlHb2JOTmkwUWl1Tl9IdjR5X3d3bGV0YXkwM1FCei1uMVpEa1FCSkxHaUVkMHlRdW9FcFo0R0plRWpLcnVZWUw2aEluWXRlYUE?oc=5","date":"2025-04-24","type":"trial","source":"GlobeNewswire","summary":"Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ - GlobeNewswire","headline":"Sarcopenia Clinical Trial Pipeline Appears Robust With 18+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQbVladVBMRXRrZzAydEx1bWR0bURJeXBCbFh4UkJHb1ZZX1JYa3NzWlpSRGFvUnpXWVM4cmtoR25QQXR2TGlKTjhfTjY3NlZON0tyUVBxYy16MVJMcGdlLWFaUUJ3eVE1c2Rid1ZQc2NmbnMzdmRDTldxb2hCZmsyOUw2Ti1UMy1iNVlBbGpFWF9qeTJvMnQwQm9YRnBVOXFBeWE3c2ZoaC00M1o2WnBMQm1ZRGMxUExVdUw2WFRiMHBzc0xNMU40c3VFX3QtU291X1NnQmlkYTVrX1YyX3R6RkdBZFo5RzU4Z0ZXUzBILWtGcmJXbU4ydVJnTklzOC0tS3ZfTFloWWdfNm9wcFdMVWhaRmJ2VE1IdXgzUzh2cjAzS1Y1?oc=5","date":"2025-02-21","type":"pipeline","source":"GlobeNewswire","summary":"Cell and Gene Therapies in Rare Disorders Market to - GlobeNewswire","headline":"Cell and Gene Therapies in Rare Disorders Market to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNVEJwUGRkeHZzLVdhaV9RRmdGbThzM0hHc0RTOTR0dzdtZUZYb1hQckhxMDNGRDVMem1rOVBkRm5ldERIN0xSY18xMXc1MGtOWW9QQVZrWDBBZ24xblFjRjhlaTg5MTVPU3hEUmNBNUJUZUFLTloyTGdvTkFpX1FiM0l2ajQ4U05zamtUZWpZSHhjaXRUeDFTVExtMUVTV1FsVno3TmFCREdLb0JiOU1IV3gxLTRrNmlNYnZtWmxNcDkzT1ZvMG9xd01zYWNNTGpGeUJEb2txcU9XR3JNNFZweGRyUUUwYTFIeFd3?oc=5","date":"2024-11-14","type":"pipeline","source":"GlobeNewswire","summary":"Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight - GlobeNewswire","headline":"Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxPejRGZWJpTmZNNWVJdm9YTHBrVk5xakRVV1NsbVhjQUxiVm9rbTc5OXBkMUpfVmRGMW9MOFpCcUliakR0emU4UjBrWUNIZWZQRlhoVEU1ODhHUWcxOGdkY3hIektmaGRoVDJMX1hTSllXTnBjbi1qYlE3cHY5QTN1SW1VcHpnc1NJbDdpcElkZW5JbmNiZ24taE5sVWRWZ0VIVkNYOHdvSTZXYVpKOXZDSFpNLVFlOEZJaFFxQkFLckM4WlA1aTJwT01XcW4xREsya0JYT1JJcHRHYmJwMExJNzRmeEYzZU1kTVNNdm5kVUlzN2xvcEJpWG8wNnBoU000N2Z4N2FvSU5pY29zeVFHNkVMbUU3RzhSbFh0a0hQNVE0eVFOQk4wdjBZYlg?oc=5","date":"2024-08-15","type":"pipeline","source":"GlobeNewswire","summary":"Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire","headline":"Global Non-Steroidal Anti-Inflammatory Drugs Market is","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPM1ZJa2Utb3RoRVhsVGQ4QVhlS19lVkhmMkdWdzEzVUF6MERqOTRsOGMzb3pjOWhMR0VTTTRJajZJalhHaFQ1SUpkeHpRYVhmLUF3VlhJSEZ6X05PNzF0aTUyZ1U1YTQ0U1NwaDE1b1UzeGhCaXRVSzFrRlZRcF9JQW9JMUpRTVptaENqMDNqSW1IRWNjd3F1U0x1QkFPT0hvSnc?oc=5","date":"2024-01-22","type":"pipeline","source":"citybiz","summary":"SIGA Appoints Diem Nguyen, Ph.D., MBA, as Chief Executive Officer - citybiz","headline":"SIGA Appoints Diem Nguyen, Ph.D., MBA, as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5sU2ZlWmdXTTUxUjYwaWpOOTBKU2JmazcyeU40YVREOFlPanBXUWc0T3B4eXNjdDZjNTRfNTJuLUJpS0RlcUk2VEFpcXg1RWk2Z3JYY3lqVkFldlhTUGFDOVRRaklUdWlYYXIzR0l6OUlkSThfYUJLbDJiQWg?oc=5","date":"2023-12-29","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2023: Reneo reduces workforce by 70%; Oxurion cuts staff down to 10 - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2023: Reneo reduces workforce by 70%; Oxurion cuts staff down to 10","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQcjdsUERKVFRPZERoUE91dm9GVElfdWs4cGlfTjJ1dXNpcEhoTm9hNktoMDBlN0xBRzB6cEx2dUNtX09LODBzQ3FUbWRETzhLNkZ5dkVaRGh0MTNmMmZHTG1PLTc1TTJfZ2NJalhhT1VJS0ZOSnM1NUZKWENOdEN4d0d1cjV1MnlDTnRNMERBd3R2aWJTbkRHazZXS0tkaU40YTU0VTZrNW1lb0NuNUtvUkZ6d0lRR3g3dXFiQTRqa2xNczJxSmVCRnVkTDZQT0g3UkhBak54QlhHSm1lU0RJQmVoczRpdw?oc=5","date":"2023-02-09","type":"pipeline","source":"BioWorld News","summary":"BIO CEO 2023: Despite high prevalence of pain and addiction, clinical efforts drop, funding flat, BIO report finds - BioWorld News","headline":"BIO CEO 2023: Despite high prevalence of pain and addiction, clinical efforts drop, funding flat, BIO report finds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOMzJfMnUxaXo1ZkdTc1VaNEhVdlp4S09FVGZsY1lXN3huZG00M1ZOUEhIUHBSNmljbExXMEtqejhJT0JIelF1ZmtzR1ptRVRYTW03RFBRNVdMZ1RjcUdhREhBaVYxZkdEOWhFVUZsaTROTXo4NzVGV2RWZVE5SnBnMVRkVVNxRF9GWnN6V19XY2FqZ1Rzdi1BVFZuZDBwdUx0aEp0RUpNTQ?oc=5","date":"2021-08-27","type":"pipeline","source":"BioWorld News","summary":"Non-viral gene therapy developer Xalud brings in a $30M series C - BioWorld News","headline":"Non-viral gene therapy developer Xalud brings in a $30M series C","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}